Matthew Barcus's questions to Vanda Pharmaceuticals Inc (VNDA) leadership • Q3 2024
Question
Matthew Barcus, on for Andrew Tsai, asked how Vanda is balancing the Fanapt and PONVORY launches, if the Q3 PONVORY inventory destocking was resolved, the size of the PONVORY sales force, and the expected timing for marketing efforts to impact revenue. He also inquired about the company's strategy for its early-stage pipeline, including potential partnerships.
Answer
CEO Mihael Polymeropoulos clarified that Fanapt and PONVORY have separate, specialized sales forces. Executive Kevin Moran confirmed the PONVORY inventory destocking was a temporary issue related to the distribution transition from Janssen and was resolved in October. He stated the PONVORY sales force numbers around 30 representatives and that the impact of marketing efforts should begin to be reflected in revenue later this year and into 2025. Dr. Polymeropoulos described the pipeline strategy as maintaining a balanced portfolio and that partnering decisions would be evaluated as assets mature.